Cyclophosphamide Pill
Phase 2Small molecule
Cyclophosphamide Pill is one of 41 small molecule programs targeting Pancreas Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Rhabdomyosarcoma
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Verzenio
Eli LillyApproved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Camptosar
PfizerPhase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Cosmegen
RRECORDATI GROUP
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Malignancies1 trial
Pancreas Cancer1 trial
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01088789·71 enrolled
Rhabdomyosarcoma1 trial
Evolutionary Therapy for Rhabdomyosarcoma
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04388839·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cyclophosphamide Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKiromic BioPharma Inc.